☆ 4.7 Article

Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study

BIOMOLECULES (2023)

Related references

Note: Only part of the references are listed.

Letter Rheumatology

Systemic lupus erythematosus and COVID-19: what we know so far

Giuseppe. A. A. Ramirez et al.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Review Virology

Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis

Behnam Amani et al.

Summary: This study examined the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19. A total of 23 studies involving 314,353 patients were included in the analysis. The findings showed significant differences between the Paxlovid and no-Paxlovid groups in terms of mortality rate, hospitalization rate, PCR negative conversion time, and hospitalization or death rate.

JOURNAL OF MEDICAL VIROLOGY (2023)

Add to Collection

Article Immunology

Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study

S. Reshwan K. Malahe et al.

Summary: The Omicron variant of the SARS-CoV-2 virus causes less severe illness in immunocompromised patients compared to previous variants. However, hospitalization rates are still high and symptoms tend to persist for a longer duration. Additional interventions are needed to reduce the disease burden in these vulnerable individuals.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Article Oncology

Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy

Francesco Ciccimarra et al.

Summary: This study aims to explore the pattern of use of monoclonal antibodies/antiviral therapies approved for early COVID-19 treatment in non-hospitalized patients from England and Italy. The prevalence of use of mAbs/antivirals increased slowly up to 2.0-3.0% of all patients diagnosed with SARS-CoV-2 infection in both countries from December 2021 to October 2022. The trend of individual drug use varied in relation to predominant SARS-CoV-2 variants with some differences across countries. Nirmatrelvir/ritonavir was the most frequently prescribed antiviral in both countries in the most recent period, following scientific societies' guidelines.

BIODRUGS (2023)

Add to Collection

Article Rheumatology

Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab

Anthony J. Ocon et al.

Summary: This article reports a longitudinal study on rheumatologic patients receiving rituximab therapy who were administered Evusheld as a preventive measure, and it was confirmed that Evusheld is effective in preventing SARS-CoV-2 infection. The study suggests that using Evusheld as part of a preventive intervention is feasible for high-risk populations.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2023)

Add to Collection

Article Infectious Diseases

Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study

Ili Margalit et al.

Summary: This study assessed the effect of remdesivir on COVID-19 mortality among elderly individuals using real-world data. The results showed that remdesivir reduced mortality in patients requiring oxygen support or non-invasive mechanical ventilation, but no association was found among patients necessitating invasive mechanical ventilation.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Add to Collection

Article Pharmacology & Pharmacy

The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19

Aline de Almeida Oliveira et al.

Summary: After almost 3 years of the COVID-19 pandemic, the development and dissemination of knowledge and products have not stopped due to the evolving virus and new variants. This study aims to analyze the current landscape of neutralizing monoclonal antibodies (nAbs) for COVID-19, providing valuable information for decision-making in scientific and pharmaceutical organizations.

JOURNAL OF PHARMACEUTICAL INNOVATION (2023)

Add to Collection

Article Medicine, General & Internal

Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study

Amita Ketkar et al.

Summary: The study aimed to estimate the risk of COVID-19 in patients with immunocompromising conditions, determine the prevalence and incidence rates of COVID-19 by specific condition, and describe healthcare resource utilization and costs. The findings showed that immunocompromised populations are at substantial risk of severe COVID-19 outcomes, leading to increased costs and healthcare resource utilization. Effective prophylactic options are needed for these high-risk populations.

CURRENT MEDICAL RESEARCH AND OPINION (2023)

Add to Collection

Letter Medicine, General & Internal

Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes

Brian E. McGarry et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Immunology

Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18-50 Years

Jeremy Samuel Faust et al.

Summary: Nirmatrelvir/ritonavir use in vaccinated adults aged 18-50 years with serious comorbidities was associated with improved clinical outcomes. However, patients without significant comorbidities had no association of benefit. Identifying high-risk patients may help improve outcomes and reduce overprescription.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Letter Medicine, General & Internal

Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes

Brian E. McGarry et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Rheumatology

Coronavirus disease 2019 in patients with Behcet's disease: a report of 59 cases in Iran

Farhad Shahram et al.

Summary: This study retrospectively examined the clinical characteristics, disease course, management, and outcomes of COVID-19 infection in patients with Behcet's disease in Iran. The results showed that the incidence of COVID-19 infection in BD patients was not higher than the general population, with a milder form of disease and lower morbidity and mortality rate. Most patients were on immunosuppressive drugs or had comorbidities other than BD, and there was no significant impact on the course of BD.

CLINICAL RHEUMATOLOGY (2022)

Add to Collection

Article Virology

Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection

Yotam Bronstein et al.

Summary: Immunocompromised patients are at increased risk of persistent COVID-19 disease. Two patients with hematologic malignancies hospitalized for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection showed viral evolution, including new spike gene mutations, following treatment with anti-SARS-CoV-2 antibodies preparations. These cases demonstrate the potential evolution of antibody-resistant SARS-CoV-2 infections in immunocompromised patients.

JOURNAL OF MEDICAL VIROLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Jennifer Hammond et al.

Summary: In high-risk, unvaccinated adults, treatment of Covid-19 with nirmatrelvir plus ritonavir can significantly reduce the risk of hospitalization and death, with good safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

R. L. Gottlieb et al.

Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Rheumatology

COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance

Bonnie L. Bermas et al.

Summary: This study describes the impact of COVID-19 on pregnancy outcomes in patients with rheumatic disease. The results show that pregnant women with rheumatic disease had favorable outcomes during the COVID-19 infection, with no deaths reported. Most patients did not receive specific medication treatment for COVID-19. Although the data is limited, it provides cautious optimism for pregnancy outcomes in women with rheumatic disease compared to other series of pregnant women with COVID-19.

JOURNAL OF RHEUMATOLOGY (2022)

Add to Collection

Article Infectious Diseases

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader et al.

Summary: A study conducted in COVID-19 patients admitted to hospital and requiring oxygen support found that remdesivir did not show significant clinical benefits compared to standard care alone.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach

Rafael Dal-Re et al.

Summary: The first two oral antivirals, molnupiravir and nirmatrelvir-ritonavir, are now available in many countries for the treatment of mild-to-moderate COVID-19 in high-risk non-hospitalised patients. They should be prescribed within 5 days of symptom onset and after confirming the SARS-CoV-2 infection. However, their availability will be limited due to manufacturing constraints.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates

Liliana Rodrigues et al.

Summary: This article provides an overview of the main developments in COVID-19 treatment and the contribution of drug repurposing. It also introduces a new drug repurposing strategy and lists 11 compounds that may be effective against COVID-19.

MOLECULES (2022)

Add to Collection

Article Immunology

The Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study

Maria Gerosa et al.

Summary: This study investigates the safety of anti-SARS-CoV-2 vaccines in systemic lupus erythematosus (SLE) patients. The results show that some patients experienced side effects after vaccination, with constitutional symptoms and immunosuppressive regimen users being more affected. A small number of patients experienced disease flare, but no hospitalizations or deaths occurred. It is recommended to vaccinate SLE patients with anti-SARS-CoV-2 vaccines, with consideration for personalized treatment adjustments.

VACCINES (2022)

Add to Collection

Letter Infectious Diseases

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients

Gregory Destras et al.

LANCET MICROBE (2022)

Add to Collection

Article Rheumatology

Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave

Yumeko Kawano et al.

Summary: This study investigated temporal trends in the incidence and severity of COVID-19 among patients with systemic autoimmune rheumatic diseases. The proportion of patients with severe COVID-19 has decreased over time, particularly during the most recent time periods, including the initial Omicron wave. Unvaccinated individuals had a higher proportion of severe cases compared to vaccinated individuals.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α

Alexis Mathian et al.

Summary: This study finds that neutralizing and non-neutralizing autoantibodies against type-I interferons (IFNs-I) are present in patients with systemic lupus erythematosus (SLE). Neutralizing anti-IFN-alpha antibodies are associated with reduced IFN-alpha levels and a decreased likelihood of developing active disease, but they increase the risk of herpes zoster and severe COVID-19 pneumonia. Severe COVID-19 pneumonia in SLE patients is mainly associated with combined neutralization of different IFNs-I.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Letter Rheumatology

Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination

Giuseppe A. Ramirez et al.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Letter Rheumatology

Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series

George E. Fragoulis et al.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Infectious Diseases

Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19

Emmanuel Lafont et al.

Summary: This study suggests that targeted treatment for COVID-19, including antiviral drugs or monoclonal antibodies, is safe and effective in immunocompromised patients, especially those at high risk.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Letter Infectious Diseases

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection

Fangfang Sun et al.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Rheumatology

Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort Analysis

Cassandra M. Calabrese et al.

Summary: Patients with immune-mediated inflammatory diseases (IMIDs) receiving B cell-depleting therapy (BCDT), even when vaccinated with SARS-CoV-2 vaccines, are susceptible to infection and often experience severe outcomes.

ARTHRITIS & RHEUMATOLOGY (2022)

Add to Collection

Article Immunology

Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Eloy E. Ordaya et al.

Summary: This study reports the clinical characteristics of patients who developed COVID-19 shortly after receiving Tixagevimab-cilgavimab, highlighting the need for additional measures to prevent COVID-19 during periods of high transmission of the SARS-CoV-2 virus.

OPEN FORUM INFECTIOUS DISEASES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity

Mario Cano-Munoz et al.

Summary: The SARS-CoV-2 spike protein plays a crucial role in virus attachment and fusion with cells. The HR1 and HR2 regions of the spike protein are potential therapeutic targets for COVID-19. A study designed chimeric proteins that mimic stable HR1 helical trimers and strongly bind to HR2, showing broad inhibitory activity against different virus strains. Antibody responses against the HR1 mimetic proteins were found in sera from COVID-19 convalescent donors, but not in sera from uninfected donors.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2022)

Add to Collection

Letter Rheumatology

Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity

Cassandra Calabrese et al.

RMD OPEN (2022)

Add to Collection

Article Medicine, General & Internal

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

Summary: This study presents the final results of the Solidarity trial and meta-analyses of mortality in relevant trials. The findings suggest that remdesivir does not have a significant effect on COVID-19 patients who are already on ventilators. However, it does have a small effect against death or progression to ventilation in other hospitalized patients.

LANCET (2022)

Add to Collection

Letter Infectious Diseases

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection

Fangfang Sun et al.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Review Immunology

COVID-19 in Immunocompromised Hosts: What We Know So Far

Monica Fung et al.

Summary: The COVID-19 pandemic caused by SARS-CoV-2 has led to significant morbidity and mortality globally. The impact of the disease on immunosuppressed patients, such as cancer patients and transplant recipients, remains unclear. Further research is needed to determine the risk of COVID-19 severity and death in immunocompromised patients.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Coronavirus disease 2019 outcomes in heart transplant recipients: a single-center case series

Farah Naghashzadeh et al.

Summary: This study investigated 13 heart transplant recipients with coronavirus disease 2019, highlighting the range of symptoms, clinical severity, and disease course in these patients, with some requiring hospitalization and others managing symptoms in the outpatient setting. Unfortunately, one patient passed away, but none experienced clinically overt rejection. The importance of vigilance and testing in various clinical presentations for better management in this patient population was emphasized.

JOURNAL OF MEDICAL CASE REPORTS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

Add to Collection

Article Immunology

Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year

Giuseppe A. Ramirez et al.

Summary: The impact of COVID-19 on patients with SLE appears to be moderate and can be significantly modulated by public health policies, including vaccination. Factors such as age, prednisone use, and infected relatives were found to be most significantly associated with COVID-19 infection among SLE patients.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Rheumatology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld et al.

Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

COVID-19 in Children With Rheumatic Diseases in the Spanish National Cohort EPICO-AEP

Cristina Calvo et al.

JOURNAL OF RHEUMATOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Influenza infection as a trigger for systemic lupus erythematosus flares resulting in hospitalization

Young Bin Joo et al.

Summary: There is a significant association between influenza infection and SLE flares resulting in hospitalization. Influenza infection must be considered as a risk factor for flares in all SLE patients regardless of age, sex, medications, and comorbidities.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Microbiology

Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy

Yusri Taha et al.

Summary: Two cases of persistent SARS-CoV-2 infection were successfully cleared with the monoclonal antibody combination casirivimab and imdevimab (REGN-COV2), highlighting the potential benefit of REGN-COV2 therapy for antibody deficient individuals. Further clinical studies are warranted to assess the effectiveness of REGN-COV2 in this patient population, especially in the context of emerging variants of concern like Omicron.

ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2021)

Add to Collection

Article Multidisciplinary Sciences

Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses

Arinjay Banerjee et al.

Summary: Recent studies have shown that SARS-CoV-2 proteins can inhibit human type I interferon responses, and the timing and extent of interferon production are associated with COVID-19 severity. SARS-CoV-2 infection induces a type I interferon response in vitro and in moderate cases of COVID-19, with physiological levels of IFNa being sufficient to suppress SARS-CoV-2 replication in human airway cells.

ISCIENCE (2021)

Add to Collection

Article Oncology

Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy

Anna Furlan et al.

Summary: Four NHL patients with SARS-CoV-2 pneumonia after rituximab therapy showed early relapse and prolonged disease course despite initial treatment with remdesivir and steroids, but had rapid and significant response to convalescent hyperimmune plasma and extended course of remdesivir. These clinical observations suggest that the immunological effects of rituximab treatment in NHL patients should be considered for proper choice of SARS-CoV-2 laboratory tests and guiding therapeutic approaches.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Review Immunology

Neutralizing monoclonal antibodies for treatment of COVID-19

Peter C. Taylor et al.

Summary: The study discusses the clinical utility of neutralizing monoclonal antibody therapies targeting SARS-CoV-2, emphasizing the importance of patient stratification, biomarkers, risk factors, and other clinical considerations.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Review Immunology

Retroviruses in the pathogenesis of systemic lupus erythematosus: Are they potential therapeutic targets?

Rossella Talotta et al.

AUTOIMMUNITY (2020)

Add to Collection

Review Microbiology

Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19

Annsea Park et al.

CELL HOST & MICROBE (2020)

Add to Collection

Editorial Material Immunology

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Shibo Jiang et al.

TRENDS IN IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Surgery

A proposed strategy for management of immunosuppression in heart transplant patients with COVID-19

Monica Ahluwalia et al.

CLINICAL TRANSPLANTATION (2020)

Add to Collection

Editorial Material Immunology

Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2

Rocktotpal Konwarh

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 A Randomized Clinical Trial

Christoph D. Spinner et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Multidisciplinary Sciences

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Qian Zhang et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Paul Bastard et al.

SCIENCE (2020)

Add to Collection

Article Pediatrics

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance

[Anonymous]

PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE (2020)

Add to Collection

Article Rheumatology

Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study

Giuseppe A. Ramirez et al.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)

Add to Collection

Review Rheumatology

How compelling are the data for Epstein-Barr virus being a trigger for systemic lupus and other autoimmune diseases?

Anette Draborg et al.

CURRENT OPINION IN RHEUMATOLOGY (2016)

Add to Collection

Article Rheumatology

Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus

Rudolf Pullmann et al.

ARTHRITIS AND RHEUMATISM (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.